Data Insights

(Tipiracil hydrochloride + trifluridine) by Taiho Oncology for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

(Tipiracil hydrochloride + trifluridine) is under clinical development by Taiho Oncology and currently in Phase II for Metastatic Adenocarcinoma of...

Likelihood of Approval and Phase Transition Success Rate Model - (Tipiracil Hydrochloride + Trifluridine) in Metastatic Adenocarcinoma of The Pancreas

Data Insights

TAS-0612 by Taiho Oncology for Solid Tumor: Likelihood of Approval

TAS-0612 is under clinical development by Taiho Oncology and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - TAS-0612 in Solid Tumor

Data Insights

(Tipiracil hydrochloride + trifluridine) by Taiho Oncology for Rectal Cancer: Likelihood of Approval

(Tipiracil hydrochloride + trifluridine) is under clinical development by Taiho Oncology and currently in Phase II for Rectal Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - (Tipiracil Hydrochloride + Trifluridine) in Rectal Cancer

Data Insights

(Azacitidine + cedazuridine) by Taiho Oncology for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval

(Azacitidine + cedazuridine) is under clinical development by Taiho Oncology and currently in Phase III for Chronic Myelomonocytic Leukemia (CMML)....

Data Insights

(Azacitidine + cedazuridine) by Taiho Oncology for Refractory Anemia With Ringed Sideroblasts: Likelihood of Approval

(Azacitidine + cedazuridine) is under clinical development by Taiho Oncology and currently in Phase III for Refractory Anemia With Ringed...

Data Insights

(Azacitidine + cedazuridine) by Taiho Oncology for Refractory Anemia With Excess Blasts: Likelihood of Approval

(Azacitidine + cedazuridine) is under clinical development by Taiho Oncology and currently in Phase III for Refractory Anemia With Excess...

Data Insights

(Azacitidine + cedazuridine) by Taiho Oncology for Myelodysplastic Syndrome: Likelihood of Approval

(Azacitidine + cedazuridine) is under clinical development by Taiho Oncology and currently in Phase III for Myelodysplastic Syndrome. According to...

Data Insights

(Tipiracil hydrochloride + trifluridine) by Taiho Oncology for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

(Tipiracil hydrochloride + trifluridine) is under clinical development by Taiho Oncology and currently in Phase II for Metastatic Transitional (Urothelial)...

Data Insights

(Tipiracil hydrochloride + trifluridine) by Taiho Oncology for Rectal Cancer: Likelihood of Approval

(Tipiracil hydrochloride + trifluridine) is under clinical development by Taiho Oncology and currently in Phase II for Rectal Cancer. According...